Reilly Financial Advisors’s Intellia Therapeutics NTLA Stock Holding History

Reilly Financial Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$25K	Buy	+215	New	+$26.9K	﹤0.01%	529

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Reilly Financial Advisors's NTLA Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in Intellia Therapeutics (NTLA) in Q4 2021: 215 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #529 among its holdings.

371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

Reilly Financial Advisors held 215 shares of Intellia Therapeutics worth $25K as of Q4 2021.
Intellia Therapeutics was a new Reilly Financial Advisors position in Q4 2021.
Intellia Therapeutics made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #529 holding.
371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.